|
Canada-0-LibrariesPublic Azienda Directories
|
Azienda News:
- Imetelstat Sodium - NCI - National Cancer Institute
Imetelstat sodium works by blocking the activity of an enzyme called telomerase, which is found at high levels in cells that divide rapidly, including cancer cells Blocking this enzyme keeps cancer cells from dividing and causes them to die Imetelstat sodium is a type of targeted therapy called an enzyme inhibitor
- Imetelstat: A First-in-Class Telomerase Inhibitor for the Treatment of . . .
Imetelstat is a first-in-class, direct, and competitive inhibitor of telomerase enzymatic activity that selectively induces apoptosis of malignant clones and allows for recovery of erythropoiesis
- Oncology Drug Reference Sheet: Imetelstat - ons. org
In June 2024, imetelstat (Rytelo™) became the first telomerase inhibitor approved by the U S Food and Drug Administration (FDA) Imetelstat treats low- to intermediate-risk myelodysplastic syndromes in adults with transfusion-dependent anemia
- Imetelstat: a new addition to the therapeutic landscape of lower-risk . . .
Imetelstat is an oligonucleotide telomerase inhibitor recently approved by the US Food and Drug Administration for adults with lower-risk myelodysplasia wh
- Imetelstat (Rytelo™) - OncoLink
Imetelstat (Rytelo™) is a telomerase inhibitor How To Take Imetelstat Imetelstat is given intravenously (into a vein) The amount given and schedule are based on your size You will have your labs checked before each dose The results of your labs help guide your treatment plan You will be given diphenhydramine (Benadryl) and hydrocortisone (steroid) before your infusion to help lessen an
- FDA approves imetelstat for low- to intermediate-1 risk myelodysplasti
On June 6, 2024, the Food and Drug Administration approved imetelstat (Rytelo, Geron Corporation), an oligonucleotide telomerase inhibitor, for adults with low- to intermediate-1 risk
- Imetelstat-mediated alterations in fatty acid metabolism to . . . - Nature
Imetelstat is a first-in-class telomerase inhibitor with clinical efficacy in myelofibrosis and myelodysplastic syndromes
- Imetelstat: Finally a disease-modifying treatment for lower-risk . . .
This finding suggests that imetelstat may establish itself as a truly disease-modifying treatment for lower-risk MDSs It will be interesting to see whether combining imetelstat with “rescue” treatments will weaken its anti-tumor effect or, hopefully, may further improve hematopoietic output in patients with lower-risk MDSs
- ACCC | Updated NCCN Guidelines Recommend Imetelstat for Symptomatic . . .
On July 26, Geron Corporation announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology (NCCN Guidelines) for the treatment of to recommend RYTELO™ (imetelstat) as a Category 1 and 2A treatment of symptomatic anemia in patients with lower-risk Myelodysplastic Syndromes Treatments are classified as Category 1 and 2A when there is
|
|